MP19-06 MESENCHYMAL STEM-CELL THERAPY ALLEVIATES INTERSTITIAL CYSTITIS BY ACTIVATING WNT SIGNALING PATHWAY

Abstract

You have accessJournal of UrologyStem Cell Research1 Apr 2015MP19-06 MESENCHYMAL STEM-CELL THERAPY ALLEVIATES INTERSTITIAL CYSTITIS BY ACTIVATING WNT SIGNALING PATHWAY Miho Song, Junsoo Park, and Myung-Soo Choo Miho SongMiho Song More articles by this author , Junsoo ParkJunsoo Park More articles by this author , and Myung-Soo ChooMyung-Soo Choo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.998AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Interstitial cystitis (IC) is a devastating disease with no reliable treatment, but the appropriate applications of stem cell therapy remain unproven. This study evaluated the therapeutic potency of using human umbilical cord-blood derived mesenchymal stem cells (UCB-MSC) to treat IC in a rat model and investigate its responsible molecular mechanism. METHODS IC was induced in 10-weeks-old female Sprague-Dawley rats via the instillation of 0.1 M HCl or PBS (sham). After 1 week, human UCB-MSC (IC+MSC) or PBS (IC) was directly injected into the submucosal layer of the bladder. Cystometric parameters, histological examination, immunostaining, and gene expression were measured at 1 week after intervention. Statistical analysis were performed by one-way ANOVA with the Bonferroni post hoc testing. RESULTS A single injection of human UCB-MSCs significantly attenuated the irregular and decreased voiding interval in the IC group. Accordingly, denudation of the epithelium and increased inflammatory responses, mast cell infiltration, neurofilament production, and angiogenesis were observed in the IC group. These actions were prevented in the IC+MSC group. The injected UCB-MSCs successfully engrafted to the stromal and epithelial tissues and activated the Wnt signaling cascade. Interference with Wnt and epidermal growth factor receptor (EGFR) activity by small molecules abrogated the benefits of MSC therapy. CONCLUSIONS This is the first report that provides an experimental evidence of the therapeutic effects and molecular mechanisms of MSC therapy to IC using an orthodox rat animal model. Our findings not only provide the basis for clinical trials, but also advance our understanding of IC pathophysiology. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e217 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Miho Song More articles by this author Junsoo Park More articles by this author Myung-Soo Choo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...